Strategic Initiative

Slingshot members are tracking this corporate initiative:

Alexion (ALXN) And Eidos' (EIDX) subsidiary - BridgeBio (BBIO) Agree On Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine License

Source Link:: https://news.alexionpharma.com/press-release/product-news/alexion-and-bridgebio-announce-japanese-license-agreement-eidos-transthyr

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ALXN

100%

EIDX

100%

BBIO

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details - Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan -
- Eidos to receive upfront payment of $25 million and equity investment of $25 million, with potential for additional Japanese-based milestone- & royalty-dependent payments -

https://news.alexion...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Sep 09, 2019

Projected Implementation:

Q3, 2019

Relevance Tracked Until:

Q4, 2019

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Amyloidosis, Attr Amyloidosis, Ag10